Glycosphingolipids of cultured human colon carcinoma cells and their drug-resistant sublines

John MeKibbin, Laurie Arcolano, Karl Anders Karlsson, Goran Larson, Jan Thurin, Michael Brattain

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Human colon carcinoma cells were analyzed for lipid phosphorus, cholesterol and glycosphingolipids. Ceramide mono-, di- and trihexosides and sulfatides were isolated by column and thin-layer chromatography and determined quantitatively on the basis of their hexose content. The complex lipid fractions so isolated were only partially resolved with the material available. Gangliosides GM2 and 6M2 and globoside were major components of the fraction and were determined on the basis of their hexose, hexosamine and neuraminic acid content. The HCT 116, 116a and 116b cells contained no fucolipids. Cell lines resistant to mitomycin C, teniposide and etoposide were developed and analyzed. Over the 5 year period of the study sulfatides declined to about one-fourth of their original amounts in both parent and drug-adapted cells. HCT 116 cells adapted to mitomycin C and teniposide had 30% less ceramide monohexoside and a 45% greater cholesterol to lipid phosphorus ratio than the parent cells. Reductions in ceramide dihexoside in the drug-adapted cells were greater than those of the ceramide monohexoside. Galabiosyl ceramide was the major ceramide dihexoside in all the cells and accumulated in HCT 116a to levels 4-6-fold greater than that of the other lines as the only dihexoside.

Original languageEnglish (US)
Pages (from-to)235-246
Number of pages12
JournalBiochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism
Volume958
Issue number2
DOIs
Publication statusPublished - Feb 4 1988

    Fingerprint

Keywords

  • (Human colon carcinoma cell)
  • Antitumor drug
  • Drug resistance
  • G
  • G
  • Gal α1 → 4Galβ1 → 4Glc → ceramide
  • Gal αl → 4Gal → ceramide
  • GalNAβ1 → 4[NeuAcα2 → 3]Galβ1 → 4G1 → ceramide
  • GalNacβ1 → 3Galα1 → 4Galβ1 → 4Glc → ceramide
  • Galβ1 → 3GalNAcβ1 → 4[NeuAcα2 → 3]Galβ1 → 4Glc → ceramide
  • Galβ1 → 3[Fucα1 → 4]GlcNAcβ1 → 3Galβ1 → 4Glc → ceramide
  • Galβ1 → 4Glc → ceramide
  • Galβ1 → 4GlcNAcβl → 3Galβ1 → 4Glc → ceramide
  • Galβ1 → 4[Fuc αl → 3]GlcNAcβ1 → 3Galβ1 → 4Glc → ceramide
  • Glycosphingolipid
  • HPTLC
  • Lewis a fucolipid
  • Lewis a isomer or 'X hapten'
  • NeuAc α2 → 8NeuAc α2 → 3Galβ1 → 4GlcNAcβl→ 3Galβ1→ 4Glc→ ceramide
  • NeuAca2 → 3Galβ1 → 4[Fucα1 → 3]GlcNAcβ1 → 3Galβ1 → 4Glc → ceramide
  • NeuAcα2 → 3Galβ1 → 3[Fucαl → 4]GlcNAcβ1 → 3Galβ1 → 4Glc → ceramide
  • NeuAcα2 → 3Galβ1 → 4Glc → ceramide
  • NeuAcα2 → 3Galβ1 → 4GlcNAcβ1 → 3Galβ1 → 4Glc → ceramide
  • NeuAcα2 → 8NeuAcα2 → 3Galβ1 → 4Glc → ceramide
  • TLC
  • disialosyl paragloboside
  • g
  • g
  • galabiosylceramide
  • globoside
  • globotriaosyl ceramide
  • high-perofrmance thin-layer chromatography
  • lactosyl ceramide
  • paragloboside
  • sialosyl 'X'
  • sialosyl Lewis a
  • sialosyl paragloboside
  • thin-layer chromatography

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Endocrinology

Cite this